Antisense regulation of oncogenes in human cancer

Critical Reviews in Oncogenesis

Volumn 7, Issue 3-4, 1996, Pages 151-190

  Mukhopadhyay, Tapas ^a   Roth, Jack A ^a,b  

^a Dept Thorac/Cardiovasc Surg ^*  (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Antisense; Gene regulation; Oncogene

Indexed keywords

COMPLEMENTARY RNA;

CANCER THERAPY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENETIC ENGINEERING; HUMAN; ONCOGENE; PROTEIN PROCESSING; REVIEW;

EID: 0030413992     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v7.i3-4.20     Document Type: Review

References (251)

1. Abe, J., W. Zhow, J. Taguchi, N. Takuwa, K. Miki, H. Okazak, K. Kurokawa, M. Kumada, and Y. Takuwa: Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun., 984:16-24 (1994).
2. Alemany, R., S. B. Ruan, M. Kataoka, P. E. Koch, T. Mukhopadhyay, J. A. Roth, and W. W. Zhang: Growth inhibitory effect of anti-k-ras adenovirus on lung cancer cells. Cancer Gene Ther., 3:296-301 (1996).
3. Allsopp, T. E., S. Kiselev, S. Wyatt, and A. M. Davies: Role of Bcl-2 in the brain-derived neurotrophic factor survival response. Eur. J. Neurosci., 7:1266-1272 (1995).
4. Ambrose, D., M. Resnicoff, D. Coppola, C. Sell, M. Miura, S. Jameson, R. Baserga, and R. Rubin: Growth regulation of human glioblastoma T98G cells by insulin-like growth factor-1 and its receptor. J. Cell. Physiol., 159:92-100 (1994).
5. Amini, S., V. DeSeau, S. Reddy, D. Shalloway, and J. B. Bolen: Regulation of pp60c-src synthesis by inducible RNA complementary to c-src mRNA in polyomavirus-transformed rat cells. Mol. Cell. Biol., 7:2305-2316 (1986).
6. Anderson, M. W., S. H. Reynolds, M. You, and R. M. Maronpot: Role of protooncogene activation in carcinogenesis (review). Environ. Health Perspect., 98:13-24 (1992).
7. Aoki, K., T. Yoshida, T. Sugimura, and M. Terada: Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res., 55:3810-3816 (1995).
8. Arteaga, C. L. and J. T. Holt: Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in mice. Cancer Res., 56:1098-1103 (1996).
9. Augustyns, K., G. Godard, C. Hendrix, A. Van Aerschot, J. Rozenski, T. Saison-Behmoaras, and P. Herdewijn: Hybridization specificity, enzymatic activity and biological (Ha-ras) activity of oligonucleotides containing 2,4-dideoxy-beta-D-erythro-hexopyranosyl nucleosides. Nucleic Acids Res., 21:4670-4676 (1993).
10. Bakhshi, A., J. P. Jensen, P. Goldman, J. J. Wright, O. W. McBride, A. L. Epstein, and S. J. Korsmeyer: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell, 41:899-906 (1985).
11. Baldin, V., J. Lukas, M. J. Marcote, M. Pagano, and G. Draetta: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev., 7:812-821 (1993).
12. Barton, C. M. and N. R. Lemoine: Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br. J. Cancer, 71:429-437 (1995).
13. Barut, B., D. Chauhan, H. Uchiyama, and K. Anderson: Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J. Clin. Invest., 92:2346-2352 (1993).
14. Beaudry, A. A. and G. F. Joyce: Directed evolution of an RNA enzyme. Science, 257:613 (1992).
15. Bedi, A., B. A. Zehnbauer, J. P. Barber, S. J. Sharkis, and R. J. Jones: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood, 83:2038-2044 (1994).
16. Behl, C., U. Gogdahn, J. Winkler, R. Apfel, W., and K. Schlingensiepen: Autoinduction of platelet-derived growth factor (PDGF) A-chain mRNA expression in a human malignant melanoma cell line and growth inhibitory effects of PDGF-A chain mRNA specific antisense molecules. Biochem. Biophys. Res. Commun., 193:744-751 (1993a).
17. Behl, C., J. Winkler, U. Bogdahn, J. Meixensberg, and K. Schligensiepen: Autocrine growth regulation in neuroectodermal tumors as detected with oligodeoxy- nucleotide antisense molecules. Neurosurgery, 33:679-684 (1993b).
18. Berchem, G. J., M. Bosseler, L. Y. Sugars, H. J. Voeller, S. Zeitlin, and E. P. Gelmann: Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res., 55:735-738 (1995).
19. Bergmann, U., H. Funatomi, M. Yokoyama, H. G. Beger, and M. Korc: Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res., 55:2007-2011 (1995).
20. Bi, S., F. Lanza, and J. M. Goldman: The abnormal p53 proteins expressed in CML cell lines are nonfunctional. Leukemia, 7:1840-1845 (1993).
21. Bi, S., F. Lanza, and J. M. Goldman: The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leu-kemia hemopoiesis. Cancer Res., 54:582-586 (1994).
22. Bishop, J. M.: Molecular themes in oncogenesis. Cell, 64:235-248 (1991).
23. Bishop, M. R., P. L. Iversen, E. Bayever, J. G. Sharp, T. C. Greiner, B. L. Copple, R. Ruddon, G. Zon, J. Spinolo, M. Arneson, J. O. Armitage, and A. Kessinger: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol., 14:1320-1326 (1996).
24. Bondurant, M. C., T. Yamashita, K. Muta, S. B. Krantz, and M. J. Koury: C-myc expression affects proliferation but not terminal differentiation or survival of explanted erythroid progenitor cells. J. Cell. Physiol., 168:255-263 (1996).
25. Bongartz, J. P., A. M. Aubertin, P. G. Milhaud, and B. Lebleu: Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res., 22:4681-4688 (1994).
26. Brugg, B., D. Reddy, and A. Matus: Attenuation of microtubule-associated protein 1B expression by antisense oligodeoxynucleotides inhibits initiation of neurite outgrowth. Neuroscience, 52:489-496 (1993).
27. Brysch, W., E. Magal, J. C. Louis, M. Kunst, I. Klinger, R. Schlingensiepen, and K. H. Schlingensiepen: Inhibition of p185c-erbB-2 protooncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation. Cancer Gene Ther., 1:99-105 (1994).
28. Busch, H.: The final common pathway of cancer (review). Cancer Res., 50:4830-4838 (1990).
29. Busch, R. K., L. Periaky, B. C. Valdez, D. Henning, and H. Busch: Apoptosis in human tumor cells following treatment with p120 antisense oligodeoxynucleotide ISIS 3466. Cancer Lett., 86:151-157 (1994).
30. Cai, D. W., T. Mukhopadhyay, and J. A. Roth: Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther., 2:199-205 (1995).
31. Campos, L., O. Sabido, J. P. Rouault, and D. Guyotat: Effects of BCL-2 antisense oligodeoxy-nucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood, 84:595-600 (1994).
32. Capaccioli, S., A. Quattrone, N. Schiavone, A. Calastretti, E. Copreni, A. Bevilacqua, G. Canti, L. Gong, S. Morelli, and A. Nicolin: A bcl-2/lgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines. Oncogene, 13:105-115 (1996).
33. Carter, G. and N. R. Lemoine: Antisense technology for cancer therapy: does it make sense? Br. J. Cancer, 67:869-876 (1993).
34. Celano, P., C. M. Berchtold, D. L. Kizer, A. Weeraratna, B. D. Nelkin, S. B. Baylin, and R. A. Casero, Jr.: Characterization of an endogenous RNA transcript with homology to the antisense strand of the human c-myc gene. J. Biol. Chem., 267:15092-15096 (1992).
35. Chang, E. H., P. S. Miller, C. Cushman, K. Devadas, K. F. Pirollo, P. O. Ts'o, and Z. P. Yu: Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry, 30:8283-8286 (1991).
36. Chen, Z., P. Kamath, S. Zhang, M. M. Weil, and E. J. Shillitoe: Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Ther., 2:263-271 (1995).
37. Chen, Z., P. Kamath, S. Zhang, L. St. John, K. Adler-Storthz, and E. J. Shillitoe: Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Cancer Gene Ther., 3:18-23 (1996).
38. Ciardiello, F., G. Tortora, C. Bianco, M. P. Selvam, F. Basolo, G. Fontanini, F. Pacifico, N. Normanno, R. Brandt, M. G. Persico et al.: Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene, 1:291-298 (1994).
39. Cleary, M. L., S. D. Smith, and J. Sklar: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/ immunoglobulin transcript resulting from the t(14;18) translocation. Cell, 47:19-28 (1986).
40. Cohen, J. S.: Antisense oligodeoxynucleotides as antiviral agents. Antiviral Res., 16:121-133 (1991).
41. Coleman, J., P. J. Green, and M. Inouye: The use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes. Cell, 37:429-436 (1984).
42. Cotter, F. E., P. Johnson, P. Hall, C. Pocock, N. Al Mahdl, J. K. Cowell, and G. Morgan: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, 9:3049-3055 (1994).
43. Crooke, S. T. and B. Lebleu: Antisense Research and Application. CRC Press, Boca Raton, FL (1993).
44. Daaka, Y. and E. Wickstrom: Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res., 5:267-275 (1990).
45. Delafontaine, P., A. Anwar, H. Lou, and L. Ku: G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor receptor is required for thrombin induced mitogenesis of rat aortic smooth muscle cells. J. Clin. Invest., 97:139-145 (1996).
46. De Lord, C., R. D. Clutterbuck, R. L. Powles, T. Min, J. C. Titley, and J. L. Millar: Human Philadelphia chromo- some-positive chronic myeloid leukemia: a potential model for antisense therapy. Exp. Hematol., 21:826-828 (1993).
47. Deng, G. and E. R. Podack: Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc. Natl. Acad. Sci. U.S.A., 90:2189-2193 (1993).
48. Deng, G., Z. Eh, Y. Xu, and Y. Lu: Activation of oncogene c-Ha-ras in gastric cancer of Chinese patients. Semin. Surg. Oncol., 10:83-87 (1994).
49. Desoize, B.: Anticancer drug resistance and inhibition of apoptosis [review]. Anticancer Res., 14:2291-2294(1994).
50. Dominski, Z. and R. Kole: Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A., 90:8673-8677 (1993).
51. Dosaka-Akita, H., K. Akie, H. Hiroumi, I. Kinoshita, Y. Kawakami, and A. Murakami: Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer. Cancer Res., 55:1559-1564 (1995).
52. Durland, R. H., D. J. Kessler, S. Gunnell, M. Duvic, B. M. Pettitt, and M. E. Hogan: Binding of triple helix-forming oligonucleotides to sites in gene. Biochemistry, 30:9246-9255 (1991).
53. Duroux, I., G. Godard, M. Boidot-Forget, G. Schwab, C. Helene, and T. Saison-Behmoaras: Rational design of point mutation-selective antisense DNA targeted to codon 12 of Ha-ras mRNA in human cells. Nucleic Acids Res., 23:3411-3418 (1995).
54. Dyson, N., P. M. Howley, K. Munger, and E. Harlow: The human papilloma virus 16 E7 oncoprotein is able to bind to retinoblastoma gene product. Science, 243:936-937 (1989).
55. Eastham, J. A. and T. E. Ahlering: Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line. J. Urol., 156:1186-1188 (1996).
56. Feng, M., G. Cabrera, J. Deshane, K. J. Scanlon, and D. T. Curiel: Neoplastic reversion accomplished by high-efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res., 55:2024-2028 (1995).
57. Fonagy, A., C. Swiderski, M. Dunn, and J. W. Freeman: Antisense-mediated specific inhibition of P120 protein expression prevents G1- to S-phase transition. Cancer Res., 52:5250-5256 (1992).
58. Fonagy, A., C. Swiderski, A. M. Ostrovsky, W. E. Bolton, and J. W. Freeman: Effect of nucleolar P120 expression level on the proliferation capacity of breast cancer cells. Cancer Res., 54:1859-1864 (1994).
59. Forster, A. C. and R. H. Symons: Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell, 49:211-220 (1987).
60. Freeman, J. W., P. McGrath, V. Bondada, N. Selliah, H. Ownby, T. Maloney, R. K. Busch, and H. Busch: Prognostic significance of proliferation-associated nucleolar antigen P120 in human breast carcinoma. Cancer Res., 51:1973-1978 (1991).
61. Freytag, S. O.: Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1. Mol. Cell. Biol., 8:1614-1624 (1988).
62. Funato, T., T. Shitara, T. Tone, L. Jiao, M. Kashani-Sabet, and K. J. Scanlon: Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem. Pharmacol., 48:1471-1475 (1994).
63. Georges, R. N., T. Mukhopadhyay, Y. J. Zhang, N. Yen, and J. A. Roth: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res., 53:1743-1746 (1993).
64. Gerlach, W. L., D. Llewellyn, and J. Haseloff: Construction of a plant disease resistance gene from the satellite RNA of tobacco rinspot virus. Nature (London), 328: 802-805 (1987).
65. Gewirtz, A. M.: Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia. Leuk. Lymphoma, 1:131-137 (1993).
66. Gillardon, F., I. Moll, and E. Uhlmann: Inhibition of c-Fos expression in the UV-irradiated epidermis by topical application of antisense oligodeoxynudleotides suppresses activation of proliferating cell nuclear antigen. Carcinogenesis, 16:1853-1856 (1995).
67. Gray, G. D., O. M. Hernandez, D. Hebel, M. Root, J. M. Pow-Sang, and E. Wickstrom: Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res., 53:577-580 (1993).
68. Gryaznov, S., T. Skorski, C. Cucco, M. Nieborowska-Skorska, C. Y. Chiu, D. Lloyd, J. K. Chen, M. Koziolkiewicz, and B. Calabretta: Oligonucleotide N3′ → P5′ phosphoramidates as antisense agents. Nucleic Acids Res., 24:1508-1514 (1996).
69. Hamada, K., M. Sakaue, R. Alemany, W. W. Zhang, Y. Horio, J. A. Roth, and M. F. Mitchell: Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol. Oncol., 63:219-227 (1996).
70. Harel-Bellan, A., A. T. Brini, D. K. Ferris, P. Robin, and W. L. Farrar: In situ detection of a heat-shock regulatory element binding protein using a soluble synthetic enhancer sequence. Nucleic Acids Res., 17:4077-4087 (1989).
71. Haruna, K., M. Hikida, Y. Ohsugi, and H. Ohmori: The secondary antigen-specific IgE response in murine lymphocytes is resistant to blockage by anti-IL4 antibody and an antisense oligodeoxynucleotide for IL4 mRNA. Cell Immunol., 515:52-64 (1993).
72. 1. Nature, 328:445-449 (1987).
73. Helene, C. and J. Toulme: Specific regulation of gene expression by antisense, sense, and antidene nucleic acids. Biochim. Biophys. Acta., 1049:99-125 (1990).
74. Hendrix, C., J. Anne, B. Joris, A. Van Aerschot, and P. Herdewijn: Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA. Biochem. J., 314:655-661 (1996).
75. Herschlag, D.: Implication in ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc. Natl. Acad. Sci. U.S.A., 88:6921-6925 (1991).
76. Hockenbery, D. M., M. Zutter, W. Hickey, M. Nahm, and S. J. Korsmeyer: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. U.S.A., 88:6961-6965 (1991).
77. Hockenbery, D. M., Z. N. Oltvai, X. M. Yin, C. L. Milliman, and S. J. Korsmeyer: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75:241-251 (1993).
78. Hu, G., W. Liu, E. G. Hanania, S. Fu, T. Wang, and A. B. Deisseroth: Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Cancer Gene Ther., 2:19-32 (1995).
79. Huang, Y., R. Snyder, M. Kligshteyn, and E. Wickstrom: Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate. Mol Med., 1:647-658 (1995).
80. Hung, W. C., J. S. Huang, and L. Y. Chuang: Antisense oligodeoxynucleotides targeted against different regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression. Biochem. Biophys. Res. Commun., 220:719-723 (1996).
81. Hunts, J., G. Merlino, I. Pastan, and N. Shimizu: Reduction of EGF receptor synthesis by antisense RNA vectors. FEBS Lett., 206:319-322 (1986).
82. Iotsova, V. and D. Stehelin: Antisense p53 provokes changes in HeLa cell growth and morphology. Eur. J. Cell Biol., 68:122-132 (1995).
83. Ishiwatari, H., N. Hayasaka, H. Inoue, M. Yutsudo, and A. Hakura: Degradation of p53 only is not sufficient for the growth stimulatory effect of human papillomavirus 16 E6 oncoprotein in human embryonic fibroblasts. J. Med. Virol., 44:243-249 (1994).
84. Izant, J. G. and H. Weintraub: Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell, 36:1007-1015 (1984).
85. Izant, J. G. and H. Weintraub: Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science, 229:343-352 (1985).
86. Janicek, M. F., B. U. Sevin, H. N. Nguyen, and H. E. Averette: Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines. Gynecol. Oncol., 59:87-92 (1995).
87. Jaskulski, D., J. K. deRiel, W. E. Mercer, B. Calabretta, and R. Baserga: Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science, 240:1544-1546 (1988).
88. Johnson, T. R., J. Trojan, D. D. Anthony, S. D. Rudin, M. L. Tykocinski, and J. Ilan: Gene therapy of rat brain glioblastoma by an episome-based transcriptional cassette expressing antisense IGF-I cDNA. Indian J. Biochem. Biophys., 31:1-13 (1994).
89. Kappel, C. C., M. C. Velez-Yanguas, S. Hirschfeld, and L. J. Helman: Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res., 54:2803-2807 (1994).
90. Kashani-Sabet, M., T. Funato, T. Tone, L. Jiao, W. Wang, E. Yoshida, B. I. Kashfinn, T. Shitara, A. M. Wu, J. G. Moreno, S. T. Traweek, T. E. Ahlering, and K. J. Scanlon: Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res. Dev., 2:3-15 (1992).
91. Kashani-Sabet, M., T. Funato, V. A. Florenes, O. Fodstad, and K. J. Scanlon: Suppression of the neoplastic pheno-type in vivo by an anti-ras ribozyme. Cancer Res., 54:900-902 (1994).
92. Keith, F. J., D. A. Bradbury, Y. M. Zhu, and N. H. Russell: Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia, 9:131-138 (1995).
93. Keller, E. T. and W. B. Ershler: Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J. Immunol., 154:4091-4098 (1995).
94. Khosla, S., M. J. Oursler, M. J. Schroeder, and N. L. Eberhardt: Transforming growth factor-beta 1 induces growth inhibition of a human medullary thyroid carcinoma cell line despite an increase in steady state c-myc messenger ribonucleic acid levels. Endocr. J., 135:1887-1993 (1994).
95. Kiehntopf, M., M. A. Brach, T. Licht, S. Petschauer, L. Karawajew, C. Kirschning, and F. Herrmann: Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity. EMBO J., 13:4645-4652 (1994).
96. Kijima, H., H. Ishida, T. Ohkawa, M. Kashani-Sabet, and K. J. Scanlon: Therapeutic applications of ribozymes (review). Pharmacol. Ther., 68:247-267 (1995).
97. Kim, H. G. and D. M. Miller: Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter. Biochemistry, 34:8165-8171 (1995).
98. Kim, S. and B. Wold: Stable reduction of thymidine kinase activity in cells expressing high levels of antisense RNA. Cell, 42:129-138 (1985).
99. Kim, S. H. and T. R. Cech: Three-dimensional model of the active site of the self-splicing rRNA precursor of tetrahymena. Proc. Natl. Acad. Sci. U.S.A., 84:8788-8792 (1987).
100. Kim, Y. H., M. A. Buchholz, F. J. Chrest, and A. A. Nordin: Up-regulation of c-myc induces the gene expression of the murine homologues of p34cdc2 and cyclin-dependent kinase-2 in T lymphocytes. J. Immunol., 152:4328-4335 (1994).
101. Kitada, S., T. Miyshita, S. Tanaka, and J. Reed: Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res. Dev., 3:157-169 (1993).
102. Kitada, S., S. Takayama, K. De Riel, S. Tanaka, and J. C. Reed: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev., 4:71-79 (1994).
103. Kobayashi, H., T. Dorai, J. F. Holland, and T. Ohnuma: Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1(PGY1) ribozyme. Cancer Res., 54:1271-1275 (1994).
104. Kobayashi, S., M. Teramura, I. Sugaware, K. Oshimi, and H. Mizoguchi: Interleukin-11 acts as an autocrine growth factor for human megakaryoblastic cell lines. Blood, 81:889-893 (1993).
105. Koizumi, M., S. Iwai, and E. Ohtsuka: Construction of a series of several self-cleaving RNA duplexes using synthetic 21-mers. FEBS Lett., 228:228-230 (1988).
106. Koizumi, M., Y. Hayase, S. Iwai, H. Kamiya, H. Inoue, and E. Ohtsuka: Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res., 17:7059-7071 (1989).
107. Koizumi, M., H. Kamiya, and E. Ohtsuka: Ribozymes designed to inhibit transformation of NIH/3T3 cells by the activated c-Ha-ras gene. Gene, 117:179-184 (1992).
108. Kopper, L. and I. Kovalszky: Antisense tumor therapy (a dream under construction) (review). In Vivo, 8:781-786 (1994).
109. Kronenwett, R., R. Haas, and G. Sczakiel: Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J. Mol. Biol., 259:632-644 (1996).
110. Kruger, K., P. J. Grabowski, A. J. Zaug, J. Sands, D. E. Gottschling, and T. R. Cech: Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of tetrahymena. Cell, 31:147-157 (1982).
111. Kukuchi, Y. and N. Sasaki: Site-specific cleavage of natural mRNA sequences by newly designed hairpin catalytic RNAs. Nucleic Acids Res., 19:6751-6755 (1991).
112. Lacetena, R. M. and G. Cesareni: Interaction between RNA1 and the primer precusor in the regulation of ColEl replication. J. Mol. Biol., 170:635-650 (1983).
113. Landreth, K. S., R. Narayanan, and K. Dorshkind: Insulin-like growth factor-I regulates pro-B cell differentiation. Blood, 80:1207-1212 (1992).
114. Lane, D. P. and L. V. Crawford: T-antigen is bound to host protein in SV40-transformed cells. Nature, 351:453-456 (1979).
115. Lange, W., M. Daskalakis, J. Finke, and G. Dolken: Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Lett., 338:175-178 (1994).
116. + chronic myeloid leukemia cells with p53 antisense phosphorothioate oligonucleotides. Brit. Med. J., 90:8-14 (1995).
117. Ledwith, B. J., S. Manam, A. R. Kraynak, W. W. Nichols, and M. O. Bradley: Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene. Mol. Cell. Biol., 10:1545-1555 (1990).
118. Leonetti, C., I. D'Agnano, F. Lozupone, A. Valentini, T. Geiser, G. Zon, B. Calabretta, G. C. Citro, and G. Zupi: Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl. Cancer Inst., 88:391-393 (1996).
119. Levi, B. Z., J. W. Kasik, and K. Ozato: c-fos antisense RNA blocks expression of c-fos gene in F9 embryonal carcinoma cells. Cell Different. Dev., 25:95-101 (1988).
120. Levi, B. Z. and K. Ozato: Constitutive expression of c-fos antisense RNA blocks c-fos gene induction by interferon and by phorbol ester and reduces c-myc expres- sion in F9 embryonal carcinoma cells. Genes Dev., 2:554-566 (1996).
121. Levine, A. J.: The tumor suppressor genes. Annu. Rev. Biochem., 62:623-651 (1993).
122. Lewalle, P. and P. Martiat: Inhibition of P210 expression in chronic myeloid leukemia: oligonucleotides and/or transduced antisense sequences (review). Leuk. Lymphoma, 1:139-143 (1993).
123. Li, M.X., H. Lonial, R. Citarella, D. Lindh, L. Colina, and R. Kramer: Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Ther., 3:221-229 (1996).
124. Linzer, D. I. H. and A. J. Levine: Characterization of a 54 kDa cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell, 17:43-52 (1979).
125. Loke, S. L., C. Stein, X. Zhang, M. Avigan, J. Cohen, and L. M. Neckers: Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis. Curr. Top. Microbiol. Immunol., 141:282-289 (1988).
126. Long, L., R. Rubin, R. Baserga, and P. Brodt: Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res., 55:1006-1009 (1995).
127. Lu, G. R., C. J. Wu, Y. Ke, X. Xiong, Y. J. Li, J. M. Liu, Y. Xu, W. Xu, J. Y. Li, G. R. Deng et al.: Inhibited neoplastic phenotype by the c-Ha-ras antisense RNA. Sci. China B., 34:1485-1491 (1991).
128. Mahdi, T., A. Brizard, C. Millet, P. Dore, J. Tanzer, and A. Kitzis: In vitro p53 and/or Rb antisense oligonucleotide treatment in association with growth factors induces the proliferation of peripheral hematopoietic progenitors. J. Cell Sci., 108:1287-1293 (1995).
129. Marcu, K. B., S. A. Bossone, and A. J. Patel: myc function and regulation. Annu. Rev. Biochem., 61:809-860 (1992).
130. Marcus-Sekura, C. J., A. M. Woerner, K. Shinozuka, G. Zon, and G. V. Quinnan, Jr.: Comparative inhibition of chloramphenicol acetytransferase gene expression by antisense oligonucleotide analogues having alkyl. phosphotriester, methylphosphonate and phosphorothioate linkages. Nucleic Acids Res., 15:5749-5763 (1987).
131. Marschall, P., J. B. Thomson, and F. Eckstein: Inhibition of gene expression with ribozymes (review). Cell. Mol. Neurobiol., 14:523-538 (1994).
132. Marthinuss, J., L. Lawrence, and M. Seiberg: Apoptosis in Pam212, an epidermal keratinocyte cell line: a possible role for bcl-2 in epidermal differentiation. Cell, 6:239-250 (1995).
133. Martiat, P., P. Lewalle, A. S. Taj, M. Philippe, Y. Larondelle, J. L. Vaerman, C. Wildmann, J. M. Goldman, and J. L. Michaux: Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibil the proliferation of BCR/ABL-containing cell lines. Blood, 81:502-509 (1993).
134. Melton, D.: Injected antisense RNAs specifically block messenger RNA translation in vivo. Proc. Natl. Acad. Sci. U.S.A., 82:144-148 (1985).
135. Mercola, D., A. Rundell, J. Westwick, and S. A. Edwards: Antisense RNA to the c-fos gene: restoration of density-dependent growth arrest in a transformed cell line. Biochem. Biophys. Res. Commun., 147:288-294 (1987).
136. Mercola, D., J. Westwick, A. Y. Rundell, E. D. Adamson, and S. A. Edwards: Analysis of a transformed cell line using antisense c-fos RNA. Gene, 72:253-265 (1988).
137. Methia, N., F. Louache, W. Vainchenker, and F. Wendling: Oligodeoxynucleotides antisense to the protooncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood, 82:1395-1401 (1993).
138. Mitsudomi, T., S. M. Steinberg, M. M. Nau, D. Carbone, D. D'Amico, S. Bodner, H. K. Oie, R. I. Linnoila, J. L. Mulshine, J. D. Minna, and A. F. Gazdar: p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7:171-180 (1992).
139. Mizuno, T., M. Chou, and M. Inouye: A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). Proc. Natl. Acad. Sci. U.S.A., 81:1966-1970 (1984).
140. Moats-Staats, B. M., G. Z. Retsch-Bogart, W. A. Price, H. W. Jarvis, A. J. D'Ercole, and A. D. Stiles: Insulin-like growth factor-I (IGF-I) antisense oligodeoxynucleotide-mediated inhibition of DNA synthesis by WI-38 cells: evidence for autocrine actions of IGF-I. Mol. Endocrinol, 7:171-180 (1993).
141. Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69:1237-1245 (1992).
142. Monia, B. P., J. F. Johnston, D. J. Ecker, M. A. Zounes, W. F. Lima, and S. M. Freier: Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem., 267:19954-19962 (1992).
143. Morelli, S., A. Alama, A. Quattrone, L. Gong, E. Copreni, G. Canti, and A. Nicolin: Oligonucleotides induce apoptosis restricted to the t(14;18) DHL-4 cell. Anticancer Drug Des., 11:1-14 (1996).
144. Morgan, J. I. and T. Curran: Stimulus-transcription coupling in the nervous system: involvement of the inducible protooncogenes fos and jun. Annu. Rev. Neurosci., 14:421-451 (1991).
145. Morishita, R., G. H. Gibbons, K. E. Ellison, M. Makajima, L. Zhang, Y. Kaneda, T. Ogihara, and T. Dzau: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen Oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. U.S.A., 90:8474-8478 (1993).
146. Moroni, M. C., M. C. Willingham, and L. Beguinot: EGF-R antisense RNA blocks expression of the epidermol growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J. Biol. Chem., 267:2714-2722 (1992).
147. Morrison, R.: Suppression of basic fibroblast growth factor expression by antisense Oligodeoxynucleotides inhibits the growth of transformed human astocytes. J. Biol. Chem., 266:728-734 (1991).
148. Moser, D. R., C. D. Moser, and J. L. Campbell: cis-acting mutations that affect rop protein control of plasmid copy number. Proc. Natl. Acad. Sci. U.S.A., 81:4465-4469 (1984).
149. Mukhopadhyay, T., M. Tainsky, A. C. Cavender, and J. A. Roth: Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res., 51:1744-1748 (1991).
150. Mukhopadhyay, T. and J. A. Roth: A codon 248 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Res., 53:4362-4366 (1993).
151. Nellen, W. and C. Lichtenstein: What makes a messenger RNA antisense? Trends Biochem. Sci., 18:419-423 (1993).
152. Neuenschwander, S., C. T. Roberts, Jr., and D. LeRoith: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocr. J., 136:4298-4303 (1995).
153. Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. Devilee, T. Glover, F. S. Collins, A. Weston, R. Modali, C. C. Harris, and B. Vogelstein: Mutations in the p53 gene occur in diverse human tumor types. Nature, 342:705-708 (1989).
154. Normanno, N., M. P. Selvam, C. F. Qi, T. Saeki, G. Johnson, N. Kim, F. Ciardiello, M. Shoyab, G. Plowman, R. Brandt et al.: Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erB-2-transformed human mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A., 91:2790-2794 (1994).
155. Nunez, G., L. London, D. Hockenbery, M. Alexander, J. P. McKearn, and S. J. Korsmeyer: Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol., 144: 3602-3610 (1990).
156. Ochs, R. L., M. T. Reilly, J. W. Freeman, and H. Busch: Intranucleolar localization of human proliferating cell nucleolar antigen p120. Cancer Res., 48:6523-6529 (1988).
157. Ohta, Y., T. Tone, T. Shitara, T. Funato, L. Jiao, B. I. Kashfian, E. Yoshida, M. Horng, P. Tsai, K. Lauterbach et al.: H-ras ribozyme-mediated alteration of the human melanoma phenotype. Ann. N.Y. Acad. Sci., 716:242-253; discussion 253-6 (1994).
158. Ohta, Y., H. Kijima, M. Kashani-Sabet, and K. J. Scanlon: Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J. Investig. Dermatol., 106:275-280 (1996a).
159. Ohta, Y., H. Kijima, T. Ohkawa, M. Kashani-Sabet, and K. J. Scanlon: Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res., 24:938-942 (1996b).
160. Orson, F. M., D. W. Thomas, W. M. McShan, D. J. Kessler, and M. E. Hogan: Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes. Nucleic Acids Res., 19:3435-3441 (1991).
161. Palfner, K., M. Kneba, W. Hiddeman, and J. Bertram: Improvement of hammerhead ribozymes cleaving mdr-1 mRNA. Biol. Chem. Hoppe Seyler, 376:289-295 (1995).
162. Perez, J. R., Y. Li, C. A. Stein, S. Majumder, A. Van Oorschot, and R. Narayana: Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A., 91:5957-5961 (1994).
163. Perlaky, L., B. C. Valdez, R. K. Busch, R. G. Larson, S. M. Jhiang, W. W. Zhang, M. Brattain, and H. Busch: Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res., 52:428-436 (1992).
164. Perlaky, L., Y. Saijo, R. K. Busch, C. F. Bennett, C. K. Mirabelli, S. T. Crooke, and H. Busch: Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. Anticancer Drug Des., 8:3-14 (1993a).
165. Perlaky, L., K. Smetana, R. Busch, Y. Saijo, and H. Busch: Nucleolar and nuclear aberrations in human lox tumor cells following treatment with p-120 antisense oligonucleotide ISIS-3466. Cancer Lett., 74:125-135 (1993b).
166. Pietrzkowski, Z., R. Lammers, G. Carpenter, A. M. Soderquist, M. Limardo, P. D. Phillips, A. Ullrich, and R. Baserga: Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ., 3:199-205 (1992).
167. Postel, E. H., S. J. Flint, D. J. Kessler, and M. E. Hogan: Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc. Natl. Acad. Sci. U.S.A., 88:8227-8231 (1991).
168. Postel, E. H.Modulation of c-myc transcription by triple helix formation. Ann. N.Y. Acad. Sci., 660:57-63 (1992).
169. Rajagopal, S., S. Huang, T. L. Moskal, B. N. Lee, A. K. el-Naggar, and S. Chakrabarty: Epidermal growth factor expression in human colon and colon carcinomas: anti-sense epidermal growth factor receptor RNA down-regulates the proliferation of human colon cancer cells. Int. J. Cancer, 62:661-667 (1995).
170. Ratajczak, M. Z., N. Hijiya, L. Catani, K. DeRiel, S. M. Luger, P. McGlave, and A. M. Gewirtz: Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood, 79:1956-1961 (1992a).
171. Ratajczak, M. Z., J. A. Kant, S. M. Luger, N. Hijiya, J. Zhang, G. Zon, and A. M. Gewitz: In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A., 89:11823-11827 (1992b).
172. Reed, J. C., M. Cuddy, S. Haldar, C. Croce, P. Nowell, D. Makover, and K. Bradley: BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc. Natl. Acad. Sci. U.S.A., 87:3660-3664 (1990a).
173. Reed, J. C., C. Stein, C. Subasinghe, S. Haldar, C. M. Croce, S. Yum, and J. Cohen: Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorotioate oligodeoxynucleotides. Cancer Res., 50:6565-6570 (1990b).
174. Resnicoff, M., D. Ambrose, D. Coppola, and R. Rubin: Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab. Invest., 69:756-760 (1993).
175. Resnicoff, M., D. Coppola, C. Sell, R. Rubin, S. Ferrone, and R. Baserga: Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res., 54: 4848-4850 (1994a).
176. Resnicoff, M., C. Sell, M. Rubini, D. A. Coppola, D., R. Baserga, and R. Rubin: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res., 54:2218-2222 (1994b).
177. Rivard, N., G. L'Allemain, J. Bartek, and J. Pouyssegur: Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J. Biol. Chem., 271:18337-18341 (1996).
178. Robinson, L. A., L. J. Smith, M. P. Fontaine, H. D. Kay, C. P. Mountjoy, and S. J. Pirruccello: c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann. Thorac. Surg., 60:1583-1591 (1995).
179. Robinson-Benion, C., K. E. Salhany, S. R. Hann, and J. T. Holt: Antisense inhibition of c-myc expression reveals common and distinct mechanisms of growth inhibition by TGF beta and TNF alpha. J. Cell Biochem., 45:188-195 (1991).
180. Rosenberg, U. B., A. Preiss, and S. Seifert: Production of phenocopies by Kruppel antisense RNA injection into Drosophila embryos. Nature, 313:703 (1985).
181. Roth, J. A., T. Mukhopadhyay, M. A. Tainsky, K. Fang, A. G. Casson, and P. M. Schneider: Molecular approaches to prevention and therapy of aerodigestive tract cancers [review]. Monogr. Natl. Cancer Inst., 15-21 (1992).
182. Roth, J. A.: Gene replacement strategies for cancer. Israel J. Med. Sci., 32:89-94 (1996).
183. Rowley, P. T., P. C. Keng, and B. A. Kosciolek: The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells. Leukemia, 20:473-480 (1996).
184. Roy, B., J. Beamon, E. Balint, and D. Reisman: Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell. Biol., 14:7805-7815 (1994).
185. Saijo, Y., L. Perlaky, B. C. Valdez, R. K. Busch, D. Henning, W. W. Zhang, and H. Busch: The effect of antisense p120 construct on p120 expression and cell proliferation in human breast cancer MCF-7 cells. Cancer Lett., 68:95-104 (1993).
186. Saison-Behmoaras, T., B. Tocque, I. Rey, M. Chassignol, N. T. Thuong, and C. Helene: Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J., 10 (5):1111-1118 (1991).
187. Sakakura, C., A. Hagiwara, H. Tsujimoto, K. Ozaki, T. Sakakibara, T. Oyama, M. Ogaki, T. Imanishi, J. Yamazaki, and T. Takahashi: Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the ki-ras gene. Anticancer Drugs, 6:553-561 (1995).
188. Sala, A. and B. Calabretta: Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. Proc. Natl. Acad. Sci. U.S.A., 89:10415-10419 (1992).
189. Sala, A., N. C. Nicolaides, A. Engelhard, T. Bellon, D. C. Lawe, A. Arnold, X. Grana, A. Giordano, and B. Calabretta: Correlation between E2F-1 requirement in the S phase and E2F-1 transactivation of cell cycle-related genes in human cells. Cancer Res., 54:1402-1406 (1994).
190. Sarnow, P., Y. S. Ho, J. Williams, and A. J. Levine: Adenovirus E1B-58 kDa tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kDa cellular protein in transformed cells. Cell, 28:387-396 (1982).
191. Sarver, N., E. M. Cantin, P. S. Chang, J. A. Zaia, P. A. Ladne, D. A. Stephens, and J. J. Rossi: Ribozymes as potential anti-HIV-1 therapeutic agents. Science, 247: 1222-1225 (1990).
192. Scanlon, K., L. Jiao, T. Funato, W. Wang, and T. Tone: Ribozyme-mediated cleavages of c-fos mRNA reduce gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl. Acad. Sci. U.S.A., 88: 10591-10595 (1991).
193. Schadendorf, D., A. Moller, B. Algermissen, M. Worm, M. Sticherling, and B. Czarnetzki: IL-8 produced by human malignant melanoma cells in vitro is an essen-tial autocrine growth factor. J. Immunol., 151:2667-2675 (1993).
194. Schilbach, K., P. Pollwein, M. Schwab, R. Handgretinger, J. Treuner, D. Niethammer, and G. Bruchelt: Reduction of N-myc expression by antisense RNA is amplified by interferon: possible involvement of the 2-5A system. Biochem. Biophys. Res. Commun., 170:1242-1248 (1990).
195. Schlingensiepen, K., R. Schlingensiepen, and M. Kunst: Opposite functions of jun-B and c-jun in growth regulation and neuronal differentiation. Dev. Genet., 14:305-312 (1993).
196. Schrump, D. S., A. Chen, and U. Consoli: Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther., 3:131-135 (1996).
197. Schwab, G., C. Chavany, I. Duroux, G. Goubin, J. Lebeau, C. Helene, and T. Saison-Behmoaras: Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. U.S.A., 91:10460-10464 (1994).
198. Selivanova, G. and K. G. Wiman: p53: a cell cycle regulator activated by DNA damage [review]. Adv. Cancer Res., 66:143-180 (1995).
199. Sell, C., M. Rubini, R. Rubin, J. P. Liu, A. Efstratiadis, and R. Baserga: Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. U.S.A., 90:11217-11221 (1993).
200. Shapiro, D. N., B. G. Jones, L. H. Shapiro, P. Dias, and P. J. Houghton: Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyo-sarcoma. J. Clin. Invest., 94:1235-1242 (1994).
201. Simons, R. W., B. C. Hoopes, W. R. McClure, and N. Kleckner: Three promoters near the termini of IS10: pIN, pOUT, and Pill. Cell, 34:673-682 (1983).
202. Sioud, M., J. B. Natvig, and O. Forre: Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. J. Mol. Biol., 223:831-835 (1992).
203. Skilling, J. S., R. C. Squatrito, J. P. Connor, T. Niemann, and R. E. Buller: p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol. Oncol., 60:72-80 (1996).
204. Skorski, T., C. Szczylik, L. Malaguarnera, and B. Calabretta: Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem. Cytobiol., 29:85-89 (1991).
205. Skorski, T., C. Szczylik, M. Z. Ratajczak, L. Malaguarnera, A. M. Gewirtz, and B. Calabretta: Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J. Exp. Med., 175:743-750 (1992).
206. Skorski, T., M. Nieborowska-Skorska, N. C. Nicolaides, C. Szczylik, P. Iversen, R. V. Iozzo, G. Zon, and B. Calabretta: Suppression of Philadelphia 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxy-nucleotide. Proc. Natl. Acad. Sci. U.S.A., 91:4504-4508 (1994).
207. Skorski, T., M. Nieborowska-Skorska, K. Campbell, R. V. Iozzo, G. Zon, Z. Darzynkiewicz, and B. Calabretta: Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J. Exp. Med., 182: 1645-1653 (1995a).
208. Skorski, T., M. Nieborowska-Skorska, C. Szczylik, P. Kanakaraj, D. Perrotti, G. Zon, A. Gewirtz, B. Perussia, and B. Calabretta: C-RAF-1 serine/threonine kinase is required in CR/ABL-dependent and normal hematopoiesis. Cancer Res., 55:2275-2278 (1995b).
209. Skorski, T., M. Nieborowska-Skorska, P. Wlodarski, G. Zon, R.V. Iozzo, and B. Calabretta: Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood, 88:1005-1012 (1996).
210. Skotzko, M., L. Wu, F. Anderson, E. M. Gordon, and F. L. Hall: Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res., 55:5493-5498 (1995).
211. Smetsers, T. F., T. Skorski, L. T. van de Locht, H. M. Wessels, A. H. Pennings, T. de Witte, B. Calabretta, and E. J. Mensink: Antisense BCR-ABL oligonucleotides induces apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia, 8:129-140 (1994).
212. Smetsers, T. F., L. T. van de Locht, A. H. Pennings, H. M. Wessels, T. M. deWitte, and E. J. Mensink: Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia, 9:118-130 (1995).
213. Smith, M. R., Y. Abubakr, R. Mohammad, T. Xie, M. Hamdan, and A. Al-Katib: Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther., 2:207-212 (1995).
214. Snyder, D. S., Y. Wu, J. L. Wang, J. J. Rossi, P. Swiderski, B. E. Kaplan, and S. J. Forman: Ribozyme-mediated inhi-bition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood, 82:600-605 (1993).
215. Steele, C., P. G. Sacks, K. Adler-Storthz, and E. J. Shillitoe: Effect of cancer cells of plasmids that express antisense RNA of human papillomavirus type 18. Cancer Res., 52:4706-4711 (1992).
216. Steele, C., L. M. Cowsert, and E. J. Shillitoe: Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Res., 53:2330-2337 (1993).
217. Stein, C. A., and Y.-C. Cheng: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science, 261:1004-1012 (1993).
218. Stein, C. A. and R. Narayanan: Antisense oligodeoxynucleotides (review). Curr. Opin. Oncol., 6:587-594 (1994).
219. Storey, A., D. Oates, L. Banks, L. Crawford, and T. Crook: Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res., 19:4109-4114 (1991).
220. Stout, U. T. and C. T. Caskey: Antisense RNA inhibition of endogenous genes. Methods Enzymol., 151:519-539 (1987).
221. Szczylik, C., T. Skorski, N. C. Nicolaides, L. Manzella, L. Malaguarnera, D. Venturelli, and A. M. Gewirtz: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science, 253: 562-565 (1991).
222. Szekely, L., G. Selivanova, K. P. Magnnsson, G. Klein, and K. G. Wiman: EBNA-5 - an Epstein-Barr virus encoded nuclear antigen binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. U.S.A., 90:5455-5459 (1993).
223. Tan, T. M. and R. C. Ting: In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res., 55:4599-4605 (1995).
224. Teixeira, A., J. C. Reed, and M. A. Pratt: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res., 55:3902-3907 (1995).
225. Terui, Y., Y. Furukawa, K. Sakoe, M. Ohta, and M. Saito: Expression of differentiation-related phenotypes and apoptosis are independently regulated during myeloid cell differentiation. Biochemistry, 117:77-84 (1995).
226. Thomas, T. J., C. A. Faaland, M. A. Gallo, and T. Thomas: Suppression of c-myc oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 breast cancer cells. Nucleic Acids Res., 23:3594-3599 (1995).
227. Tone, T., M. Kashani-Sabet, T. Funato, T. Shitara, E. Yoshida, B. I. Kashfian, M. Horng, O. Fodstadt, and K. J. Scanlon: Suppression of EJ cells tumorigenicity. In Vivo, 7:471-476 (1993).
228. Tortora, G., T. Clair, and Y. Cho-Chung: An antisense oligodeoxynucleotide targeted against the type IIb regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiaton in HL-60 leukemia cells without affecting phorbol ester effects. Proc. Natl. Acad. Sci. U.S.A., 87:705-708 (1990).
229. Tortora, G., H. Yokozaki, S. Pepe, T. Clair, and Y. Cho-Chung: Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A., 88:2011-2015 (1991).
230. Trojan, J., B. K. Blossey, T. R. Johnson, S. D. Rudin, M. Tykocinski, and J. Ilan: Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc. Natl. Acad. Sci. U.S.A., 89:4874-4878 (1992).
231. Trojan, J., T. R. Johnson, S. D. Rudin, J. Ilan, and M. L. Tykocinski: Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing anti-sense insulin-like growth factor I RNA. Science, 259: 94-97 (1993).
232. Trojan, J., T. R. Johnson, S. D. Rudin, B. K. Blossey, K. M. Kelley, A. Shevelev, F. W. Abdul-Karim, D. D. Anthony, M. L. Tykocinski, J. Ilan et al.: Gene therapy of murine teratocarcinoma: separate functions for insulin-like growth factors I and II in immunogenicity and differentiation. Proc. Natl. Acad. Sci. U.S.A., 91:6088-6092 (1994).
233. Tsuji, K. and K. Ogawa: Recovery from ultraviolet-induced growth arrest of primary rat hepatocytes by p53 anti-sense oligonucleotide treatment. Mol. Carcinog., 9: 167-174 (1994).
234. Usman, N., L. Beigelman, and J. A. McSwiggen: Hammerhead ribozyme engineering (review). Curr.Opin. Oncol., 6:527-533 (1996).
235. Wagner, R. W.: Gene inhibition using antisense oligodeoxynucleotides. Nature, 372:333-335 (1994).
236. Wang, S., R. J. Lee, G. Cauchon, D. G. Gorenstein, and P. S. Low: Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. U.S.A., 92:3318-3322 (1995).
237. Wang, X. W., K. Forrester, H. Yeh, M. A. Feitelson, J. R. Gu, and C. C. Harris: Hepatitis-B virus x-protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. U.S.A., 91:2230-2234 (1994).
238. Wickstrom, E., T. A. Bacon, and E. L. Wickstrom: Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res., 52:6741-6745 (1992).
239. Wickstrom, E. L., T. A. Bacon, A. Gonzalez, D. L. Freeman, G. H. Lyman, and E. Wickstrom: Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an anitsense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc. Natl. Acad. Sci. U.S.A., 85:1028-1032 (1988).
240. Wu, G. Y., J. M. Wilson, F. Shalaby, M. Grossman, D. A. Shafritz, and C. H. Wu: Receptor-mediated gene delivery in vivo. J. Biol. Chem., 266:14338-14342 (1991).
241. Wu, J., M. Wang, X. Li, and Y. Sheng: Conformation changes of p53 proteins in regulation of murine T lymphocyte proliferation. Cell. Mol. Mol Res., 39:27-31 (1993).
242. Wu, J. X., P. M. Carpenter, C. Gresens, R. Keh, H. Niman, J. W. Morris, and D. Mercola: The protooncogene c-fos is overexpressed in the majority of human osteosarcomas. Oncogene, 5:989-1000 (1990).
243. Wu, X., J. H. Bayle, D. Olson, and A. J. Levine: The p53-mdm2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132 (1993).
244. Yamada, H., S. Koizumi, M. Kimura, and N. Shimizu: Reduction of EGF receptor levels in human tumor cells transfected with an antisense RNA expression vector. Exp. Cell Res., 184:90-98 (1989).
245. Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature, 352:345-347 (1991).
246. Yonish-Rouach, E., D. Grunwald, S. Wilder, A. Kimchi, E. May, J.-J. Lawrence, P. May, and M. Oren: p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol., 13:1415-1423 (1993).
247. Yu, H. R. and R. M. Schultz: Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human-urokinase sense and antisense genes. Cancer Res., 50: 7623-7633 (1990).
248. Zhang, H., R. Kobayashi, K. Galaktionov, and D. Beach: p19Skpl and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell, 82:915-925 (1995).
249. Zhang, Y. J., T. Mukhopadhyay, L. W. Donehower, R. N. Georges, and J. A. Roth: Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum. Gene Ther., 4:451-460 (1993).
250. Zhou, P., W. Jiang, Y. J. Zhang, S. M. Kahn, I. Schieren, R. M. Santella, and I. B. Weinstein: Antisense to cyclin D1 inhibits growth and reverses the transformed pheno-type of human esophageal cancer cells. Oncogene, 11:571-580 (1995).
251. Zhu, Y. M., D. A. Bradbury, and N. H. Russell: Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br. J. Cancer, 69:468-472 (1994).